A Phase 4 interventional study of Silicone Gels and Petrolatum Ointment in Acne Scars and Acne Scars - Atrophic, sponsored by University Medical Center Ho Chi Minh City (UMC). Completed at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University Medical Center Ho Chi Minh City (UMC) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to compare the effectiveness and safety of silicone gel and white petrolatum for skin recovery after fractional CO₂ laser treatment in patients with atrophic acne scars.
The main questions it aims to answer are:
Researchers will compare silicone gel with white petrolatum in 39 patients using a randomized, double-blind, split-face design.
Participants will:
880 studies on the registry are indexed under Patient Satisfaction; 204 are open to participants now.
This study's enrollment of 39 is below the median of 96 across 626 interventional studies indexed under Patient Satisfaction.
Browse Patient Satisfaction studies →University Medical Center Ho Chi Minh City (UMC) is the lead sponsor of 35 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After topical anaesthesia (EMLA 5%, 30 minutes) and antisepsis, full-face fractional CO₂ laser was performed by the treating physician following a standard protocol, using the AcuPulse system (Lumenis) with the Deep FX handpiece (120 µm spot, Superpulse mode) at 17.5-22.5 mJ per microbeam and 5% density in a single pass, identical on both facial halves. Immediately after laser, the side to receive each product (silicone gel or white petrolatum) was determined by random draw: a container held six lots numbered 1 to 6; an odd number assigned silicone gel to the right half and white petrolatum to the left, and an even number assigned the reverse. The intervention was silicone gel (Stratacel; Stratpharma AG, Basel, Switzerland), a Class B medical device licensed by the Ministry of Health of Vietnam
Drug: Silicone Gels
After topical anaesthesia (EMLA 5%, 30 minutes) and antisepsis, full-face fractional CO₂ laser was performed by the treating physician following a standard protocol, using the AcuPulse system (Lumenis) with the Deep FX handpiece (120 µm spot, Superpulse mode) at 17.5-22.5 mJ per microbeam and 5% density in a single pass, identical on both facial halves. Immediately after laser, the side to receive each product (silicone gel or white petrolatum) was determined by random draw: a container held six lots numbered 1 to 6; an odd number assigned silicone gel to the right half and white petrolatum to the left, and an even number assigned the reverse. The comparator was white petrolatum (Vaseline; Boston plant). Both are indicated for application to injured or wounded skin .
Drug: Petrolatum Ointment
The intervention was silicone gel (Stratacel; Stratpharma AG, Basel, Switzerland), a Class B medical device licensed by the Ministry of Health of Vietnam, and the comparator was white petrolatum (Vaseline; Boston plant). Both are indicated for application to injured or wounded skin
The intervention was silicone gel (Stratacel; Stratpharma AG, Basel, Switzerland), a Class B medical device licensed by the Ministry of Health of Vietnam, and the comparator was white petrolatum (Vaseline; Boston plant). Both are indicated for application to injured or wounded skin
Scar severity
Scar severity graded with the ECCA (Clinical Evaluation Scale for Acne Scars) score. Total score range: 0 to 540 points. Higher scores mean more severe scarring.
Time frame: Baseline and 1, 2, 6 weeks post-treatment
Overall improvement
Overall improvement graded by two blinded dermatologists using the Physician Global Aesthetic Improvement Scale (PGAIS). The PGAIS typically uses a 5-point grading system comparing post-treatment results to baseline photographs or pre-treatment appearance; from "Much improved" to "Much worse".
Time frame: Baseline and 1, 2, 6 weeks post-treatment
Skin hydration
Skin hydration index was measured with Corneometer probe (Courage + Khazaka)
Time frame: Baseline and 1, 2, 6 weeks post-treatment
Transepidermal Water Loss
Transepidermal Water Loss index was measured with Tewameter probe (Courage + Khazaka)
Time frame: Baseline and 1, 2, 6 weeks post-treatment
Erythema
Erythema index was measured with Mexameter probe (Courage + Khazaka)
Time frame: Baseline and 1, 2, 6 weeks post-treatment
Plan to share: No — Individual participant data (IPD) will not be shared due to privacy concerns and institutional policies that restrict data sharing beyond the research team. Data were collected under a protocol that did not include participant consent for public or external data sharing.
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Sep 2026, 16 months.
Of 24 phase 4 interventional studies under Patient Satisfaction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Ho Chi Minh City (UMC)